乙基8-氧代-8-[4-(三氟甲基)苯基]辛酸酯 | 362669-42-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 乙基8-氧代-8-[4-(三氟甲基)苯基]辛酸酯
• 英文名称: Ethyl 7-(4-(trifluoromethyl)benzoyl)heptanoate
• 英文别名: Ethyl 8-oxo-8-(4-trifluoromethylphenyl)octanoate；ethyl 8-oxo-8-[4-(trifluoromethyl)phenyl]octanoate
• CAS: 362669-42-9
• 化学式: C₁₇H₂₁F₃O₃
• 分子量: 330.347
• InChiKey: YONPICYULMSXTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2918300090

反应信息

• 作为反应物：
  描述：

  乙基8-氧代-8-[4-(三氟甲基)苯基]辛酸酯 在 sodium hydroxide 、 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 N-hydroxy-7-(4-trifluoromethylbenzoyl)heptanamide
  参考文献：
  名称：

  Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors

  摘要：

  A series of new, structurally simple trichostatin A (TSA)-like straight chain hydroxamates were prepared and evaluated for their ability to inhibit partially purified human histone deacetylase 1 (HDAC-1). Some of these compounds such as 8m, 8n, 12, and 15b exhibited potent HDAC inhibitory activity with low nanomolar IC50 values, comparable to natural TSA. These compounds induce hyperacetylation of histones in T24 human cancer cells and significantly inhibit proliferation in. various human cancer cells. They also induce expression of p21 and cause cell cycle blocks in human cancer cells. in this paper, we describe the synthesis of these new compounds as well as structure-activity relationship results from enzyme inhibition and alterations in cellular function.

  DOI：

  10.1021/jm020154k
• 作为产物：
  描述：

  7-溴庚酸乙酯 在 三甲基氯硅烷 、 sodium iodide 、 锌 、 二溴甲烷 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 19.17h， 生成 乙基8-氧代-8-[4-(三氟甲基)苯基]辛酸酯
  参考文献：
  名称：

  Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors

  摘要：

  A series of new, structurally simple trichostatin A (TSA)-like straight chain hydroxamates were prepared and evaluated for their ability to inhibit partially purified human histone deacetylase 1 (HDAC-1). Some of these compounds such as 8m, 8n, 12, and 15b exhibited potent HDAC inhibitory activity with low nanomolar IC50 values, comparable to natural TSA. These compounds induce hyperacetylation of histones in T24 human cancer cells and significantly inhibit proliferation in. various human cancer cells. They also induce expression of p21 and cause cell cycle blocks in human cancer cells. in this paper, we describe the synthesis of these new compounds as well as structure-activity relationship results from enzyme inhibition and alterations in cellular function.

  DOI：

  10.1021/jm020154k

文献信息

• Inhibitors of histone deacetylase
  申请人：——

  公开号：US20020115826A1

  公开（公告）日：2002-08-22

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及组蛋白去乙酰化酶的抑制。本发明提供了用于抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和状况的组合物和方法。
• Inhibitors of Histone Deacetylase
  申请人：Delorme Daniel

  公开号：US20090181971A1

  公开（公告）日：2009-07-16

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶的技术。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病状的组合物和方法。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：Methylgene, Inc.

  公开号：EP1280764A2

  公开（公告）日：2003-02-05
• US7288567B2
  申请人：——

  公开号：US7288567B2

  公开（公告）日：2007-10-30
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS D'HISTONE DESACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2001070675A2

  公开（公告）日：2001-09-27

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.